JPMorgan has faced an outcry among Bear Stearns shareholders about the lowball offer, and faced the possibility that rival deals would begin to surface.
Proteomics could also be vital to the future of the pharmaceutical industry, says Jessica Chutter, managing director and co-director of biotechnology for Morgan Stanley.